secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001140361-25-011174
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol
--------------------------------------------------------------------------------

- Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.
- Cash $15.1M at Dec 31, 2024; new $5M line of credit from chairman in March 2025; cash runway through Aug 2025.
- NAVIGATE trial: varices incidence reduced 49.3% (p=0.04) in per-protocol for belapectin 2 mg vs placebo.
- In US per-protocol patients, varices reduced 68.1% (p=0.02); ITT population did not reach significance.
- Additional biomarker data expected Q2 2025; belapectin has FDA Fast Track Designation for MASH cirrhosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/0001140361-25-011174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/ef20046120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-011174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer